A practical reference on bioavailability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-03. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
==== Cannabinoids ==== According to a study published in the August 15, 2004 issue of the journal Cancer Research, cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to gliomas (brain tumors) implanted under the skin of mice, by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).
== Further reading == Mortison, JD; Sherman, DH (2010). "Frontiers and opportunities in chemoenzymatic synthesis". J Org Chem. 75 (21): 7041–51. doi:10.1021/jo101124n. PMC 2966535. PMID 20882949. Kim, Jinhyun; Lee, Sahng Ha; Tieves, Florian; Paul, Caroline E.; Hollmann, Frank; Park, Chan Beum (5 July 2019). "Nicotinamide adenine dinucleotide as a photocatalyst". Science Advances. 5 (7): eaax0501. doi:10.1126/sciadv.aax0501.
== Chemistry == KNX-100 is a synthetic small molecule and peptide fragment of the oxytocin system. Its chemical structure has been disclosed by its developers in a patent. The chemical synthesis of KNX-100 has been described. The small-molecule oxytocin receptor agonists LIT-001 and LIT-002 are derivatives of KNX-100. The more-compact small-molecule oxytocin receptor agonists WJ0679 and CA7 are also analogues of KNX-100.
Sources: en.wikipedia.org
If Gaddafi's Free Officers had not preempted the Shelhis, they would have almost certainly been defeated by the combined forces of Abdul Aziz Shelhi, the deputy commander of Libya's army, and the prominent families in Cyrenaica that supported the Shelhi family. On 1 September, Gaddafi's Free Officers occupied airports, police depots, radio stations, and government offices in Tripoli and Benghazi. Gaddafi took control of the Berka barracks in Benghazi, while Umar Muhayshi occupied Tripoli barracks and Jalloud seized the city's anti-aircraft batteries. Khweldi Hameidi took over the Tripoli radio station and arrested crown prince Sayyid Hasan ar-Rida al-Mahdi as-Sanussi, forcing him to relinquish his claim to the throne. They met no serious resistance and wielded little violence against the monarchists. Once Gaddafi removed the government, he announced the foundation of the Libyan Arab Republic. Addressing the populace by radio, he proclaimed an end to the "reactionary and corrupt" regime, "the stench of which has sickened and horrified us all". Due to the coup's bloodless nature, it was initially labelled the "White Revolution", although was later renamed the "One September Revolution" after its date. Gaddafi insisted that the Free Officers' coup represented a revolution, marking the start of widespread change in the socio-economic and political nature of Libya. He proclaimed that the revolution meant "freedom, socialism, and unity", and soon implemented measures to achieve this.
== Low-level exposure == As the energy of radio frequency waves and microwaves is insufficient to directly disrupt individual chemical bonds in small or stable molecules, the effects are considered limited to thermal. Energy densities that are not sufficient to overheat the tissues are not shown to cause lasting damage. To clarify, the deep-red lightbulb in a black-and-white photographic darkroom produces a higher-energy form of radiation than microwaves. Like a microwave, this lightbulb can burn, particularly if touched, but the burn is only possible due to too much heat. A study of 20,000 radar technicians of the US Navy, who were chronically exposed to high levels of microwave radiation, did not detect increased incidence of cancer. Recent epidemiologic evidence also led to the consensus that exposure to electromagnetic fields, e.g. along power lines, did not raise incidence of leukemia or other cancers.
==== Dol ==== The dol (from the Latin word for pain, dolor) is a unit of measurement for pain. James D. Hardy, Herbert G. Wolff, and Helen Goodell of Cornell University proposed the unit based on their studies of pain during the 1940s and 1950s. They defined one dol to equal a just-noticeable difference in pain. The unit never came into widespread use and other methods are now used to assess the level of pain experienced by patients.
Sources: en.wikipedia.org
=== Cell signaling and function === As a cell adhesive substrate, CCN1 induces the activation of focal adhesion kinase, paxillin, RAC, and sustained activation of MAPK/ERK1-2. In macrophages, CCN1 also activates the transcription factor NFκB and stimulates M1 polarization. CYR61 activates Akt signaling in thymic epithelial cells, promoting their proliferation and thus thymic size growth. CCN1 has potent angiogenic activity upon endothelial cells and induces neovascularization, first demonstrated in a corneal micropocket implant assay and subsequently confirmed in a rabbit ischemic hindlimb model. CCN1 also accelerates and promotes the chondrogenic differentiation of mouse limb bud mesenchymal cells, and stimulates osteoblast differentiation but inhibits osteoclastogenesis. CCN1 is a strong inducer of reactive oxygen species accumulation in fibroblastic cells, and this activity underlies many CCN1-induced apoptosis and senescence. CYR61 is able to support cell adhesion, stimulate cell migration, promote growth factor-induced cell proliferation and differentiation in some cell types, promote apoptosis in synergy with TNF family cytokines, and induce cellular senescence in fibroblasts.
Fourthly, it is important to ensure that no single retailer monopolizes the procurement operations in an area, district or state in order to protect the local suppliers. Lastly, the predatory pricing and the anti competitive practices of these international retailers should be prohibited in order to create a playing field for local retailers SOURCE.
Koya-dofu (kōya-dōfu, 高野豆腐 in Japanese) is a freeze-dried type also known as kōri tofu (凍り豆腐, "frozen tofu"). Originally from Mount Kōya, a center of Japanese Buddhism famed for its shōjin ryōri, or traditional Buddhist vegetarian cuisine. It is said that the method of koya-dofu was discovered by accident by leaving tofu outdoors in the winter season. It is sold in freeze-dried blocks or cubes in Japanese markets. It is typically simmered in dashi, sake or mirin and soy sauce. In shōjin ryōri, vegetarian kombu dashi, made from seaweed, is used. When prepared in the usual manner, it has a spongy texture and a mildly sweet or savory flavor. The taste and flavor depend on what soup or cooking stock it was simmered in. A similar form of freeze-dried tofu, in smaller pieces, is found in instant soups (such as miso soup), in which the toppings are freeze-dried and stored in sealed pouches. Shimidōfu (凍み豆腐) is mainly consumed in the Tohoku region. While koya-dofu is made by shade-drying, shimidofu is made by sun-drying.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.